Literature DB >> 23211678

Differential in situ expression of IL-17 in skin diseases.

Mattias Fischer-Stabauer1, Alexander Boehner, Stefanie Eyerich, Teresa Carbone, Claudia Traidl-Hoffmann, Carsten B Schmidt-Weber, Andrea Cavani, Johannes Ring, Ruediger Hein, Kilian Eyerich.   

Abstract

UNLABELLED: Interleukin (IL)-17 is a key molecule for epithelial immunity and inflammation.
OBJECTIVES: To quantify IL-17 expression in situ in a large panel of cutaneous diseases. 289 samples of the 30 most common cutaneous infectious, autoimmune, inflammatory and tumor diseases were stained for IL-17 immunohistochemically. IL-17 expression strongly varied between the diseases, but was conserved within each disease. The major cellular sources of IL-17 were T cells and granulocytes. Skin diseases caused by extracellular microbials were infiltrated by many IL-17+ cells, while intracellular infections were scarcely positive for IL-17. While autoimmune diseases were mostly accompanied by IL-17+ T cells, IL-17+ granulocytes were dominant in neutrophilic dermatoses. Cutaneous diseases show a characteristic pattern of IL-17+ cellular infiltrate. These patterns are relevant for the clinician, since therapeutic approaches targeting differentiation of Th17 cells as well as direct targeting of IL-17 are or will become available.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23211678     DOI: 10.1684/ejd.2012.1854

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  16 in total

Review 1.  Secukinumab: a promising therapeutic option in spondyloarthritis.

Authors:  Hernan Maldonado-Ficco; Rodolfo Perez-Alamino; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2016-07-20       Impact factor: 2.980

2.  [Regulation of proinflammatory and anti-inflammatory Th17 cells].

Authors:  C E Zielinski
Journal:  Z Rheumatol       Date:  2013-06       Impact factor: 1.372

3.  Pyoderma gangrenosum: From historical perspectives to emerging investigations.

Authors:  Misty M Hobbs; Alex G Ortega-Loayza
Journal:  Int Wound J       Date:  2020-05-06       Impact factor: 3.315

Review 4.  Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.

Authors:  Bruce W Kirkham; Arthur Kavanaugh; Kristian Reich
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

Review 5.  Impact of community-associated methicillin resistant Staphylococcus aureus on HIV-infected patients.

Authors:  Joanna Cole; Kyle Popovich
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

Review 6.  Role of Th17 cells in skin inflammation of allergic contact dermatitis.

Authors:  Matthias Peiser
Journal:  Clin Dev Immunol       Date:  2013-08-18

Review 7.  Advances in the diagnosis and therapeutic management of atopic dermatitis.

Authors:  Christian Vestergaard; Mette Deleuran
Journal:  Drugs       Date:  2014-05       Impact factor: 11.431

8.  Acute transverse myelitis and psoriasiform dermatitis associated with Sjoegren's syndrome: a case report.

Authors:  Carolin Kurz; Silke Wunderlich; Derek Spieler; Benedikt J Schwaiger; Christian Andres; Claudia Traidl-Hoffmann; Rüdiger Ilg
Journal:  BMC Res Notes       Date:  2014-08-29

9.  Allergic contact dermatitis in psoriasis patients: typical, delayed, and non-interacting.

Authors:  Maria Quaranta; Stefanie Eyerich; Bettina Knapp; Francesca Nasorri; Claudia Scarponi; Martina Mattii; Natalie Garzorz; Anna T Harlfinger; Teresa Jaeger; Martine Grosber; Davide Pennino; Martin Mempel; Christina Schnopp; Fabian J Theis; Cristina Albanesi; Andrea Cavani; Carsten B Schmidt-Weber; Johannes Ring; Kilian Eyerich
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

10.  Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid.

Authors:  Sébastien Le Jan; Julie Plée; David Vallerand; Aurélie Dupont; Elodie Delanez; Anne Durlach; Patricia L Jackson; J Edwin Blalock; Philippe Bernard; Frank Antonicelli
Journal:  J Invest Dermatol       Date:  2014-07-19       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.